Dare BioscienceDARE +0.99%23 Gross Margin % is -59.21% as of Mar. 2026. GuruFocus rates DARE with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 737 Biotechnology companies, Dare Bioscience ranks worse than 56.99% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Dare Bioscience had a gross margin of -59.21% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Dare Bioscience Gross Margin % Related Terms
Dare Bioscience Gross Margin % Historical Data
* Premium members only.
The historical data trend for Dare Bioscience's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DARE vs TVGN, LITS, BOLD: Gross Margin % Comparison
For the Biotechnology subindustry, Dare Bioscience's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dare Bioscience Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dare Bioscience's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Dare Bioscience's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Dare Bioscience (DARE) has a Gross Margin % of -59.21% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Dare Bioscience and its competitors. Over the past decade, Dare Bioscience's Gross Margin % has ranged from 53.50 to 71.26. According to the industry distribution chart, Dare Bioscience ranks #420 out of 737 companies in the Biotechnology industry, placing it in the top 57%.
Is Dare Bioscience's Gross Margin % too high?
Dare Bioscience's current Gross Margin % is -59.21%. Over the past 10 years, this metric has ranged from a low of 53.50 to a high of 71.26. Based on the distribution chart, Dare Bioscience ranks #420 out of 737 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Dare Bioscience has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Dare Bioscience's Gross Margin % compare to TVGN and LITS?
According to the Biotechnology industry distribution chart, Dare Bioscience ranks #420 out of 737 companies for Gross Margin %. This places Dare Bioscience in the lower half of its industry. The industry median Gross Margin % is 60.92. Historically, Dare Bioscience's own Gross Margin % has ranged from 53.50 to 71.26 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Dare Bioscience and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dare Bioscience's current Gross Margin % is -59.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dare Bioscience stock overvalued right now?
Dare Bioscience (DARE) has a current Gross Margin % of -59.21%. The current Gross Margin % is -59.21%. Dare Bioscience's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Dare Bioscience (DARE), the current Gross Margin % is -59.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
23GF Score
Get the complete analysis for DARE
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DARE has been successfully added to your 
